PTPRC and neoplasm: To further interrogate immunological changes to the TdLN and tumor in an unbiased holistic manner, we performed bulk RNA-sequencing on CD45+ cells from TdLN samples from mice treated with PBS, Tx, Tx + ɑCD4, or ɑCD4 3 and 6 days following ɑ4-1BB-LAIR administration.